

 Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 22578-003US1	Application No. 10/533,799
	<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)			
	Applicant Graeme Semple, et al.		Filing Date May 4, 2005	Group Art Unit 1626

## U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	6,756,216 B2	06/29/2004	Maier			
	AB	6,541,423 B1	04/01/2003	Mayer et al.			
	AC	6,589,915 B1	07/08/2003	Mayer et al.			
	AD	6,200,925 B1	03/13/2001	Ponasik, Jr. et al.			
	AE	6,054,257	04/25/2000	Boff et al.			
	AF	4,943,574	07/24/1990	Raeymaekers et al.			
	AG	2004/0142377 A1	07/22/2004	Unett et al.			

## Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Sub class	Translation	
							Yes	No
	AH	WO06/127595 A1	11/30/2006	WIPO				
	AI	WO04/041274 A1	05/21/2004	WIPO				
	AJ	WO04/032928 A1	04/22/2004	WIPO				
	AK	WO01/57034 A1	08/09/2001	WIPO				
	AL	WO00/68228	11/16/2000	WIPO				
	AM	WO98/40420	09/17/1998	WIPO				
	AN	WO96/16059	05/30/1996	WIPO				
	AO	WO94/25446	11/10/1994	WIPO				
	AP	BE825605	08/18/1975	Belgium				
	AQ	DE4239830 A1	06/09/1993	Germany				
	AR	DE2917619 A1	11/13/1980	Germany				
	AS	EP1247810 B1	10/09/2002	EPO				
	AT	EP1191106 A1	03/27/2002	EPO				
	AU	EP0896248 A2	02/10/1999	EPO				
	AV	EP0474991 B1	10/18/1995	EPO				
	AW	EP0293978 B1	09/15/1993	EPO				
	AX	EP0481709 A1	04/22/1992	EPO				

Examiner Signature /Susannah Chung/ (06/19/2008)	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.C./

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 22578-003US1	Application No. 10/533,799
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Graeme Semple, et al.	
		Filing Date May 4, 2005	Group Art Unit 1626

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Sub class	Translation	
							Yes	No
	AY	EP0398713 A2	11/22/1990	EPO				
	AZ	JP2000330244	11/30/2000	Japan				
	AAA	JP11160880	06/18/1999	Japan				
	ABB	JP10123714	05/15/1998	Japan				
	ACC	JP10053528	02/24/1998	Japan				
	ADD	JP06184472 A	07/05/1994	Japan				
	AEE	JP06184473 A	07/05/1994	Japan				
	AFF	JP2000347391	12/15/2000	Japan				
	AGG	JP04195049 A	07/15/1992	Japan				
	AHH	JP06310829 A	11/04/1994	Japan				
	AII	JP05117557	05/14/1993	Japan				

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AJJ	Bertus <i>et al.</i> , "New and easy route to primary cyclopropylamines from nitriles", <i>Chemical Communications</i> (Cambridge, United Kingdom) (2001), (18), 1792-1793.
	AKK	Cecchetti <i>et al.</i> , "6-Aminoquinolones: A New Class of Quinolone Antibacterials?", <i>Journal of Medicinal Chemistry</i> (1995), 38(6), 973-82.
	ALL	Chang <i>et al.</i> , "Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats", <i>Diabetes</i> (1983), 32(9), 830-8.
	AMM	Coleman, "Diabetes-obesity syndromes in mice", <i>Diabetes</i> (1982), 31(Suppl 1 Pt 2), 1-6.
	ANN	Coleman, <i>et al.</i> , "Fat (fat) and tubby (tub): two autosomal recessive mutations causing obesity syndromes in the mouse", <i>The Journal of Heredity</i> (1990), 81(6), 424-7.
	AOO	Collier <i>et al.</i> , "Radiosynthesis and <i>in-vivo</i> evaluation of the pseudopeptide $\delta$ -opioid antagonist [ <sup>125</sup> I]-ITIPP( $\Psi$ )", <i>J. Labelled Cpd. Radiopharm.</i> (1999) 42(Suppl 1):S264-266.
	APP	Cornhill <i>et al.</i> , "Topographic study of sudanophilic lesions in cholesterol-fed minipigs by image analysis", <i>Arteriosclerosis</i> (Dallas, Tex.) (1985), 5(5), 415-26.
	AQQ	Delparte <i>et al.</i> , Pre- and post-translational negative effect of $\beta$ -adrenoceptor agonists on adiponectin secretion: <i>in vitro</i> and <i>in vivo</i> studies. <i>Biochemical Journal</i> (2002), 367(3), 677-685.
	ARR	Eriksson <i>et al.</i> , "Increased incidence of congenital malformations in the offspring of diabetic rats and their prevention by maternal insulin therapy", <i>Diabetes</i> (1982), 31(1), 1-6.
	ASS	Friedman <i>et al.</i> , "Tackling a weighty problem", <i>Cell</i> (1992), 69(2), 217-20.
	ATT	Gerrity <i>et al.</i> , "Diabetes-induced accelerated atherosclerosis in swine", <i>Diabetes</i> (2001), 50(7), 1654-1665.

Examiner Signature /Susannah Chung/ (06/19/2008)	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.C./

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 22578-003US1	Application No. 10/533,799
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Graeme Semple, et al.	
		Filing Date May 4, 2005	Group Art Unit 1626

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AUU	Higuchi and Stella, <i>Pro-drugs as Novel Delivery Systems</i> , Vol. 14 of the A.C.S. Symposium Series.
	AVV	Horikoshi <i>et al.</i> , Troglitazone (CS-045), a new antidiabetic drug. <i>Annual Report of Sankyo Research Laboratories</i> (1994), 46 1-57.
	AWW	Katritzky and Rees, <i>Comprehensive Heterocyclic Chemistry</i> , Pergamon Press, 1996.
	AXX	Koranyi <i>et al.</i> , "Glucose transporter levels in spontaneously obese (db/db) insulin-resistant mice", <i>Journal of Clinical Investigation</i> (1990), 85(3), 962-7.
	AYY	Larock, <i>Comprehensive Organic Transformations, A Guide to Functional Group Preparations</i> , 2 <sup>nd</sup> Edition, VCH Publishers, Inc. (1999).
	AZZ	Le Bas <i>et al.</i> , "Radioiodinated analogs of EP00652218 for the exploration of the tachykinin NK1 receptor by spect", <i>J. Labelled Cpd. Radiopharm.</i> (2001) 44(Suppl 1):S280-282.
	AAAA	Linde <i>et al.</i> , "Phenoxazine derivatives. IV, A degradation", <i>Arch. Pharm.</i> (1961), 294, 398-404.
	ABBB	Matsuda <i>et al.</i> , "Role of Adiponectin in Preventing Vascular Stenosis. The Missing Link of Adipo-Vascular axis", <i>Journal of Biological Chemistry</i> (2002), 277(40), 37487-37491.
	ACCC	Middleton <i>et al.</i> , "Fluorimines", <i>Journal of Organic Chemistry</i> (1965), 30(5), 1398-1402.
	ADDD	Paio <i>et al.</i> , "Solid-Supported Benzotriazoles: Synthetic Auxiliaries and Traceless Linkers for the Combinatorial Synthesis of Amine Libraries", <i>J. Comb. Chem.</i> (1999), 1, 317-325
	AEEE	Pan <i>et al.</i> , "Liquid phase synthesis of arylamines and its application to benzimidazolones via nucleophilic aryl substitution", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> (1999), 9(11), 1537-1540.
	AFFF	<i>Remington's Pharmaceutical Sciences</i> , 17th ed., Mack Publishing Company, Easton, Pa., (1985), 1418.
	AGGG	Roche, Edward B., editor, <i>Bioreversible Carriers in Drug Design</i> , American Pharmaceutical Association and Pergamon Press, (1987).
	AHHH	Royo <i>et al.</i> , "Effect of gemfibrozil on peripheral atherosclerosis and platelet activation in a pig model of hyperlipidemia", <i>European Journal of Clinical Investigation</i> (2000), 30(10), 843-852.
	AIII	Rudaya <i>et al.</i> , "Reactivity of azoles. I. Values of the $\sigma$ -constants of triazole and imidazole rings in benzotriazole and benzimidazole", <i>Zhurnal Organicheskoi Khimii</i> (1972), 8(1), 13-16.
	AJJJ	SciFinder Search Results, August 20, 2003, 11 pages.
	AKKK	Semple <i>et al.</i> , "1-Alkyl-benzotriazole-5-carboxylic Acids Are Highly Selective Agonists of the Human Orphan G-Protein Coupled Receptor GPR109b", <i>J. Med. Chem.</i> (2006), 49, 1227-1230.
	ALLL	Shafir, "Diabetes in Animals", <i>Diabetes Mellitus</i> , [Rifkin, H. and D Porte, Jr., editors, Elsevier Science Publishing Co, New York, ed. 4, (1990), pp. 299-340].
	AMMM	Smith and March, <i>Advanced Organic Chemistry</i> , 5 <sup>th</sup> Edition, Wiley-Interscience (2001).
	ANNN	Truett <i>et al.</i> , "Rat obesity gene fatty (fa) maps to chromosome 5: evidence for homology with the mouse gene diabetes (db)", <i>Proc. Natl. Acad. Sci USA</i> , (1991), 88(17), 7806-9.
	AOOO	Wuts and Greene, <i>Protective Groups in Organic Synthesis</i> , 3 <sup>rd</sup> Edition, John Wiley and Sons, (1999).
	APPP	Zhu <i>et al.</i> , "Synthesis and Mode of Action of <sup>125</sup> I- and <sup>3</sup> H-Labeled Thieno[2,3-c]pyridine Antagonists of Cell Adhesion Molecule Expression", <i>Journal of Organic Chemistry</i> (2002), 67(3), 943-948.

Examiner Signature /Susannah Chung/ (06/19/2008)	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.C./

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 22578-003US1	Application No. 10/533,799
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Graeme Semple, et al.	
		Filing Date May 4, 2005	Group Art Unit 1626

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AQQQ	Copy of International Search Report for PCT/US2003/035427 (4 pages).
	ARRR	Copy of International Search Report for PCT/US2006/019730 (5 pages).

Examiner Signature /Susannah Chung/ (06/19/2008)	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.C./